Global Neurodegenerative Drugs Market Growth 2025-2031
The global Neurodegenerative Drugs market size is predicted to grow from US$ 132880 million in 2025 to US$ 190180 million in 2031; it is expected to grow at a CAGR of 6.2% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
LP Information, Inc. (LPI) ' newest research report, the ?Neurodegenerative Drugs Industry Forecast? looks at past sales and reviews total world Neurodegenerative Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neurodegenerative Drugs sales for 2025 through 2031. With Neurodegenerative Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurodegenerative Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurodegenerative Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurodegenerative Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Neurodegenerative Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurodegenerative Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurodegenerative Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurodegenerative Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Neurodegenerative Drugs market?
What factors are driving Neurodegenerative Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurodegenerative Drugs market opportunities vary by end market size?
How does Neurodegenerative Drugs break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
LP Information, Inc. (LPI) ' newest research report, the ?Neurodegenerative Drugs Industry Forecast? looks at past sales and reviews total world Neurodegenerative Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neurodegenerative Drugs sales for 2025 through 2031. With Neurodegenerative Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurodegenerative Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neurodegenerative Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurodegenerative Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Neurodegenerative Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurodegenerative Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurodegenerative Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurodegenerative Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- NMDA
- SSRIs
- Dopamine Inhibitors
- Parkinson?s Disease
- Huntington Disease
- Amyotrophic Lateral Sclerosis
- Alzheimer?s Disease
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Pfizer
- Merck Serono
- Biogen Idec
- TEVA
- UCB
- Boehringer Ingelheim
- Sanofi
- GlaxoSmithKline
- Livzon Pharmaceutical
- Haisco Pharmaceutical
- Jingxin Pharmaceutical
- Dongcheng Biochemicals
- Hisun Pharmaceutical
- Luye Pharma
- Ark Pharmaceutical
- Kanghong Pharmaceutical
- Huahai Pharmaceutical
- BORA PHARMACEUTICALS
What is the 10-year outlook for the global Neurodegenerative Drugs market?
What factors are driving Neurodegenerative Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurodegenerative Drugs market opportunities vary by end market size?
How does Neurodegenerative Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurodegenerative Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Neurodegenerative Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Neurodegenerative Drugs by Country/Region, 2020, 2024 & 2031
2.2 Neurodegenerative Drugs Segment by Type
2.2.1 NMDA
2.2.2 SSRIs
2.2.3 Dopamine Inhibitors
2.3 Neurodegenerative Drugs Sales by Type
2.3.1 Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Neurodegenerative Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Neurodegenerative Drugs Sale Price by Type (2020-2025)
2.4 Neurodegenerative Drugs Segment by Application
2.4.1 Parkinson?s Disease
2.4.2 Huntington Disease
2.4.3 Amyotrophic Lateral Sclerosis
2.4.4 Alzheimer?s Disease
2.5 Neurodegenerative Drugs Sales by Application
2.5.1 Global Neurodegenerative Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Neurodegenerative Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Neurodegenerative Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Neurodegenerative Drugs Breakdown Data by Company
3.1.1 Global Neurodegenerative Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Neurodegenerative Drugs Sales Market Share by Company (2020-2025)
3.2 Global Neurodegenerative Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Neurodegenerative Drugs Revenue by Company (2020-2025)
3.2.2 Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Neurodegenerative Drugs Sale Price by Company
3.4 Key Manufacturers Neurodegenerative Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurodegenerative Drugs Product Location Distribution
3.4.2 Players Neurodegenerative Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEURODEGENERATIVE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neurodegenerative Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Neurodegenerative Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Neurodegenerative Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Neurodegenerative Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Neurodegenerative Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Neurodegenerative Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Neurodegenerative Drugs Sales Growth
4.4 APAC Neurodegenerative Drugs Sales Growth
4.5 Europe Neurodegenerative Drugs Sales Growth
4.6 Middle East & Africa Neurodegenerative Drugs Sales Growth
5 AMERICAS
5.1 Americas Neurodegenerative Drugs Sales by Country
5.1.1 Americas Neurodegenerative Drugs Sales by Country (2020-2025)
5.1.2 Americas Neurodegenerative Drugs Revenue by Country (2020-2025)
5.2 Americas Neurodegenerative Drugs Sales by Type (2020-2025)
5.3 Americas Neurodegenerative Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurodegenerative Drugs Sales by Region
6.1.1 APAC Neurodegenerative Drugs Sales by Region (2020-2025)
6.1.2 APAC Neurodegenerative Drugs Revenue by Region (2020-2025)
6.2 APAC Neurodegenerative Drugs Sales by Type (2020-2025)
6.3 APAC Neurodegenerative Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neurodegenerative Drugs by Country
7.1.1 Europe Neurodegenerative Drugs Sales by Country (2020-2025)
7.1.2 Europe Neurodegenerative Drugs Revenue by Country (2020-2025)
7.2 Europe Neurodegenerative Drugs Sales by Type (2020-2025)
7.3 Europe Neurodegenerative Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurodegenerative Drugs by Country
8.1.1 Middle East & Africa Neurodegenerative Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Neurodegenerative Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Neurodegenerative Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Neurodegenerative Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurodegenerative Drugs
10.3 Manufacturing Process Analysis of Neurodegenerative Drugs
10.4 Industry Chain Structure of Neurodegenerative Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurodegenerative Drugs Distributors
11.3 Neurodegenerative Drugs Customer
12 WORLD FORECAST REVIEW FOR NEURODEGENERATIVE DRUGS BY GEOGRAPHIC REGION
12.1 Global Neurodegenerative Drugs Market Size Forecast by Region
12.1.1 Global Neurodegenerative Drugs Forecast by Region (2026-2031)
12.1.2 Global Neurodegenerative Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Neurodegenerative Drugs Forecast by Type (2026-2031)
12.7 Global Neurodegenerative Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Neurodegenerative Drugs Product Portfolios and Specifications
13.1.3 Novartis Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Neurodegenerative Drugs Product Portfolios and Specifications
13.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Merck Serono
13.3.1 Merck Serono Company Information
13.3.2 Merck Serono Neurodegenerative Drugs Product Portfolios and Specifications
13.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Merck Serono Main Business Overview
13.3.5 Merck Serono Latest Developments
13.4 Biogen Idec
13.4.1 Biogen Idec Company Information
13.4.2 Biogen Idec Neurodegenerative Drugs Product Portfolios and Specifications
13.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Biogen Idec Main Business Overview
13.4.5 Biogen Idec Latest Developments
13.5 TEVA
13.5.1 TEVA Company Information
13.5.2 TEVA Neurodegenerative Drugs Product Portfolios and Specifications
13.5.3 TEVA Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 TEVA Main Business Overview
13.5.5 TEVA Latest Developments
13.6 UCB
13.6.1 UCB Company Information
13.6.2 UCB Neurodegenerative Drugs Product Portfolios and Specifications
13.6.3 UCB Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 UCB Main Business Overview
13.6.5 UCB Latest Developments
13.7 Boehringer Ingelheim
13.7.1 Boehringer Ingelheim Company Information
13.7.2 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolios and Specifications
13.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Boehringer Ingelheim Main Business Overview
13.7.5 Boehringer Ingelheim Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Neurodegenerative Drugs Product Portfolios and Specifications
13.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 GlaxoSmithKline
13.9.1 GlaxoSmithKline Company Information
13.9.2 GlaxoSmithKline Neurodegenerative Drugs Product Portfolios and Specifications
13.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GlaxoSmithKline Main Business Overview
13.9.5 GlaxoSmithKline Latest Developments
13.10 Livzon Pharmaceutical
13.10.1 Livzon Pharmaceutical Company Information
13.10.2 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Livzon Pharmaceutical Main Business Overview
13.10.5 Livzon Pharmaceutical Latest Developments
13.11 Haisco Pharmaceutical
13.11.1 Haisco Pharmaceutical Company Information
13.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Haisco Pharmaceutical Main Business Overview
13.11.5 Haisco Pharmaceutical Latest Developments
13.12 Jingxin Pharmaceutical
13.12.1 Jingxin Pharmaceutical Company Information
13.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Jingxin Pharmaceutical Main Business Overview
13.12.5 Jingxin Pharmaceutical Latest Developments
13.13 Dongcheng Biochemicals
13.13.1 Dongcheng Biochemicals Company Information
13.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolios and Specifications
13.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Dongcheng Biochemicals Main Business Overview
13.13.5 Dongcheng Biochemicals Latest Developments
13.14 Hisun Pharmaceutical
13.14.1 Hisun Pharmaceutical Company Information
13.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Hisun Pharmaceutical Main Business Overview
13.14.5 Hisun Pharmaceutical Latest Developments
13.15 Luye Pharma
13.15.1 Luye Pharma Company Information
13.15.2 Luye Pharma Neurodegenerative Drugs Product Portfolios and Specifications
13.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Luye Pharma Main Business Overview
13.15.5 Luye Pharma Latest Developments
13.16 Ark Pharmaceutical
13.16.1 Ark Pharmaceutical Company Information
13.16.2 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Ark Pharmaceutical Main Business Overview
13.16.5 Ark Pharmaceutical Latest Developments
13.17 Kanghong Pharmaceutical
13.17.1 Kanghong Pharmaceutical Company Information
13.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Kanghong Pharmaceutical Main Business Overview
13.17.5 Kanghong Pharmaceutical Latest Developments
13.18 Huahai Pharmaceutical
13.18.1 Huahai Pharmaceutical Company Information
13.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Huahai Pharmaceutical Main Business Overview
13.18.5 Huahai Pharmaceutical Latest Developments
13.19 BORA PHARMACEUTICALS
13.19.1 BORA PHARMACEUTICALS Company Information
13.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolios and Specifications
13.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 BORA PHARMACEUTICALS Main Business Overview
13.19.5 BORA PHARMACEUTICALS Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neurodegenerative Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Neurodegenerative Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Neurodegenerative Drugs by Country/Region, 2020, 2024 & 2031
2.2 Neurodegenerative Drugs Segment by Type
2.2.1 NMDA
2.2.2 SSRIs
2.2.3 Dopamine Inhibitors
2.3 Neurodegenerative Drugs Sales by Type
2.3.1 Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Neurodegenerative Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Neurodegenerative Drugs Sale Price by Type (2020-2025)
2.4 Neurodegenerative Drugs Segment by Application
2.4.1 Parkinson?s Disease
2.4.2 Huntington Disease
2.4.3 Amyotrophic Lateral Sclerosis
2.4.4 Alzheimer?s Disease
2.5 Neurodegenerative Drugs Sales by Application
2.5.1 Global Neurodegenerative Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Neurodegenerative Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Neurodegenerative Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Neurodegenerative Drugs Breakdown Data by Company
3.1.1 Global Neurodegenerative Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Neurodegenerative Drugs Sales Market Share by Company (2020-2025)
3.2 Global Neurodegenerative Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Neurodegenerative Drugs Revenue by Company (2020-2025)
3.2.2 Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Neurodegenerative Drugs Sale Price by Company
3.4 Key Manufacturers Neurodegenerative Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurodegenerative Drugs Product Location Distribution
3.4.2 Players Neurodegenerative Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEURODEGENERATIVE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neurodegenerative Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Neurodegenerative Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Neurodegenerative Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Neurodegenerative Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Neurodegenerative Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Neurodegenerative Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Neurodegenerative Drugs Sales Growth
4.4 APAC Neurodegenerative Drugs Sales Growth
4.5 Europe Neurodegenerative Drugs Sales Growth
4.6 Middle East & Africa Neurodegenerative Drugs Sales Growth
5 AMERICAS
5.1 Americas Neurodegenerative Drugs Sales by Country
5.1.1 Americas Neurodegenerative Drugs Sales by Country (2020-2025)
5.1.2 Americas Neurodegenerative Drugs Revenue by Country (2020-2025)
5.2 Americas Neurodegenerative Drugs Sales by Type (2020-2025)
5.3 Americas Neurodegenerative Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurodegenerative Drugs Sales by Region
6.1.1 APAC Neurodegenerative Drugs Sales by Region (2020-2025)
6.1.2 APAC Neurodegenerative Drugs Revenue by Region (2020-2025)
6.2 APAC Neurodegenerative Drugs Sales by Type (2020-2025)
6.3 APAC Neurodegenerative Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neurodegenerative Drugs by Country
7.1.1 Europe Neurodegenerative Drugs Sales by Country (2020-2025)
7.1.2 Europe Neurodegenerative Drugs Revenue by Country (2020-2025)
7.2 Europe Neurodegenerative Drugs Sales by Type (2020-2025)
7.3 Europe Neurodegenerative Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neurodegenerative Drugs by Country
8.1.1 Middle East & Africa Neurodegenerative Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Neurodegenerative Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Neurodegenerative Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Neurodegenerative Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurodegenerative Drugs
10.3 Manufacturing Process Analysis of Neurodegenerative Drugs
10.4 Industry Chain Structure of Neurodegenerative Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurodegenerative Drugs Distributors
11.3 Neurodegenerative Drugs Customer
12 WORLD FORECAST REVIEW FOR NEURODEGENERATIVE DRUGS BY GEOGRAPHIC REGION
12.1 Global Neurodegenerative Drugs Market Size Forecast by Region
12.1.1 Global Neurodegenerative Drugs Forecast by Region (2026-2031)
12.1.2 Global Neurodegenerative Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Neurodegenerative Drugs Forecast by Type (2026-2031)
12.7 Global Neurodegenerative Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Neurodegenerative Drugs Product Portfolios and Specifications
13.1.3 Novartis Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Neurodegenerative Drugs Product Portfolios and Specifications
13.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Merck Serono
13.3.1 Merck Serono Company Information
13.3.2 Merck Serono Neurodegenerative Drugs Product Portfolios and Specifications
13.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Merck Serono Main Business Overview
13.3.5 Merck Serono Latest Developments
13.4 Biogen Idec
13.4.1 Biogen Idec Company Information
13.4.2 Biogen Idec Neurodegenerative Drugs Product Portfolios and Specifications
13.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Biogen Idec Main Business Overview
13.4.5 Biogen Idec Latest Developments
13.5 TEVA
13.5.1 TEVA Company Information
13.5.2 TEVA Neurodegenerative Drugs Product Portfolios and Specifications
13.5.3 TEVA Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 TEVA Main Business Overview
13.5.5 TEVA Latest Developments
13.6 UCB
13.6.1 UCB Company Information
13.6.2 UCB Neurodegenerative Drugs Product Portfolios and Specifications
13.6.3 UCB Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 UCB Main Business Overview
13.6.5 UCB Latest Developments
13.7 Boehringer Ingelheim
13.7.1 Boehringer Ingelheim Company Information
13.7.2 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolios and Specifications
13.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Boehringer Ingelheim Main Business Overview
13.7.5 Boehringer Ingelheim Latest Developments
13.8 Sanofi
13.8.1 Sanofi Company Information
13.8.2 Sanofi Neurodegenerative Drugs Product Portfolios and Specifications
13.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Sanofi Main Business Overview
13.8.5 Sanofi Latest Developments
13.9 GlaxoSmithKline
13.9.1 GlaxoSmithKline Company Information
13.9.2 GlaxoSmithKline Neurodegenerative Drugs Product Portfolios and Specifications
13.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GlaxoSmithKline Main Business Overview
13.9.5 GlaxoSmithKline Latest Developments
13.10 Livzon Pharmaceutical
13.10.1 Livzon Pharmaceutical Company Information
13.10.2 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Livzon Pharmaceutical Main Business Overview
13.10.5 Livzon Pharmaceutical Latest Developments
13.11 Haisco Pharmaceutical
13.11.1 Haisco Pharmaceutical Company Information
13.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Haisco Pharmaceutical Main Business Overview
13.11.5 Haisco Pharmaceutical Latest Developments
13.12 Jingxin Pharmaceutical
13.12.1 Jingxin Pharmaceutical Company Information
13.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Jingxin Pharmaceutical Main Business Overview
13.12.5 Jingxin Pharmaceutical Latest Developments
13.13 Dongcheng Biochemicals
13.13.1 Dongcheng Biochemicals Company Information
13.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolios and Specifications
13.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Dongcheng Biochemicals Main Business Overview
13.13.5 Dongcheng Biochemicals Latest Developments
13.14 Hisun Pharmaceutical
13.14.1 Hisun Pharmaceutical Company Information
13.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Hisun Pharmaceutical Main Business Overview
13.14.5 Hisun Pharmaceutical Latest Developments
13.15 Luye Pharma
13.15.1 Luye Pharma Company Information
13.15.2 Luye Pharma Neurodegenerative Drugs Product Portfolios and Specifications
13.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Luye Pharma Main Business Overview
13.15.5 Luye Pharma Latest Developments
13.16 Ark Pharmaceutical
13.16.1 Ark Pharmaceutical Company Information
13.16.2 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Ark Pharmaceutical Main Business Overview
13.16.5 Ark Pharmaceutical Latest Developments
13.17 Kanghong Pharmaceutical
13.17.1 Kanghong Pharmaceutical Company Information
13.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Kanghong Pharmaceutical Main Business Overview
13.17.5 Kanghong Pharmaceutical Latest Developments
13.18 Huahai Pharmaceutical
13.18.1 Huahai Pharmaceutical Company Information
13.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
13.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Huahai Pharmaceutical Main Business Overview
13.18.5 Huahai Pharmaceutical Latest Developments
13.19 BORA PHARMACEUTICALS
13.19.1 BORA PHARMACEUTICALS Company Information
13.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolios and Specifications
13.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 BORA PHARMACEUTICALS Main Business Overview
13.19.5 BORA PHARMACEUTICALS Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neurodegenerative Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Neurodegenerative Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of NMDA
Table 4. Major Players of SSRIs
Table 5. Major Players of Dopamine Inhibitors
Table 6. Global Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 7. Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Table 8. Global Neurodegenerative Drugs Revenue by Type (2020-2025) & ($ million)
Table 9. Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global Neurodegenerative Drugs Sale Price by Type (2020-2025) & (US$/MT)
Table 11. Global Neurodegenerative Drugs Sale by Application (2020-2025) & (MT)
Table 12. Global Neurodegenerative Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Neurodegenerative Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Neurodegenerative Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Neurodegenerative Drugs Sale Price by Application (2020-2025) & (US$/MT)
Table 16. Global Neurodegenerative Drugs Sales by Company (2020-2025) & (MT)
Table 17. Global Neurodegenerative Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Neurodegenerative Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Neurodegenerative Drugs Sale Price by Company (2020-2025) & (US$/MT)
Table 21. Key Manufacturers Neurodegenerative Drugs Producing Area Distribution and Sales Area
Table 22. Players Neurodegenerative Drugs Products Offered
Table 23. Neurodegenerative Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Neurodegenerative Drugs Sales by Geographic Region (2020-2025) & (MT)
Table 27. Global Neurodegenerative Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Neurodegenerative Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Neurodegenerative Drugs Sales by Country/Region (2020-2025) & (MT)
Table 31. Global Neurodegenerative Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Neurodegenerative Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Neurodegenerative Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)
Table 35. Americas Neurodegenerative Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Neurodegenerative Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 38. Americas Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 39. APAC Neurodegenerative Drugs Sales by Region (2020-2025) & (MT)
Table 40. APAC Neurodegenerative Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Neurodegenerative Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 43. APAC Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 44. Europe Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)
Table 45. Europe Neurodegenerative Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 47. Europe Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 48. Middle East & Africa Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)
Table 49. Middle East & Africa Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 51. Middle East & Africa Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 52. Key Market Drivers & Growth Opportunities of Neurodegenerative Drugs
Table 53. Key Market Challenges & Risks of Neurodegenerative Drugs
Table 54. Key Industry Trends of Neurodegenerative Drugs
Table 55. Neurodegenerative Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Neurodegenerative Drugs Distributors List
Table 58. Neurodegenerative Drugs Customer List
Table 59. Global Neurodegenerative Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 60. Global Neurodegenerative Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 62. Americas Neurodegenerative Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Neurodegenerative Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 64. APAC Neurodegenerative Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 66. Europe Neurodegenerative Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 68. Middle East & Africa Neurodegenerative Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Neurodegenerative Drugs Sales Forecast by Type (2026-2031) & (MT)
Table 70. Global Neurodegenerative Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Neurodegenerative Drugs Sales Forecast by Application (2026-2031) & (MT)
Table 72. Global Neurodegenerative Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Novartis Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Novartis Neurodegenerative Drugs Product Portfolios and Specifications
Table 75. Novartis Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 76. Novartis Main Business
Table 77. Novartis Latest Developments
Table 78. Pfizer Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Neurodegenerative Drugs Product Portfolios and Specifications
Table 80. Pfizer Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Merck Serono Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Merck Serono Neurodegenerative Drugs Product Portfolios and Specifications
Table 85. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 86. Merck Serono Main Business
Table 87. Merck Serono Latest Developments
Table 88. Biogen Idec Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Biogen Idec Neurodegenerative Drugs Product Portfolios and Specifications
Table 90. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 91. Biogen Idec Main Business
Table 92. Biogen Idec Latest Developments
Table 93. TEVA Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. TEVA Neurodegenerative Drugs Product Portfolios and Specifications
Table 95. TEVA Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 96. TEVA Main Business
Table 97. TEVA Latest Developments
Table 98. UCB Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. UCB Neurodegenerative Drugs Product Portfolios and Specifications
Table 100. UCB Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 101. UCB Main Business
Table 102. UCB Latest Developments
Table 103. Boehringer Ingelheim Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolios and Specifications
Table 105. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 106. Boehringer Ingelheim Main Business
Table 107. Boehringer Ingelheim Latest Developments
Table 108. Sanofi Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Neurodegenerative Drugs Product Portfolios and Specifications
Table 110. Sanofi Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. GlaxoSmithKline Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. GlaxoSmithKline Neurodegenerative Drugs Product Portfolios and Specifications
Table 115. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 116. GlaxoSmithKline Main Business
Table 117. GlaxoSmithKline Latest Developments
Table 118. Livzon Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 120. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 121. Livzon Pharmaceutical Main Business
Table 122. Livzon Pharmaceutical Latest Developments
Table 123. Haisco Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 125. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 126. Haisco Pharmaceutical Main Business
Table 127. Haisco Pharmaceutical Latest Developments
Table 128. Jingxin Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 130. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 131. Jingxin Pharmaceutical Main Business
Table 132. Jingxin Pharmaceutical Latest Developments
Table 133. Dongcheng Biochemicals Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolios and Specifications
Table 135. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 136. Dongcheng Biochemicals Main Business
Table 137. Dongcheng Biochemicals Latest Developments
Table 138. Hisun Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 140. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 141. Hisun Pharmaceutical Main Business
Table 142. Hisun Pharmaceutical Latest Developments
Table 143. Luye Pharma Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Luye Pharma Neurodegenerative Drugs Product Portfolios and Specifications
Table 145. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 146. Luye Pharma Main Business
Table 147. Luye Pharma Latest Developments
Table 148. Ark Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 150. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 151. Ark Pharmaceutical Main Business
Table 152. Ark Pharmaceutical Latest Developments
Table 153. Kanghong Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 155. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 156. Kanghong Pharmaceutical Main Business
Table 157. Kanghong Pharmaceutical Latest Developments
Table 158. Huahai Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 160. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 161. Huahai Pharmaceutical Main Business
Table 162. Huahai Pharmaceutical Latest Developments
Table 163. BORA PHARMACEUTICALS Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolios and Specifications
Table 165. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 166. BORA PHARMACEUTICALS Main Business
Table 167. BORA PHARMACEUTICALS Latest Developments
Table 1. Neurodegenerative Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Neurodegenerative Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of NMDA
Table 4. Major Players of SSRIs
Table 5. Major Players of Dopamine Inhibitors
Table 6. Global Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 7. Global Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Table 8. Global Neurodegenerative Drugs Revenue by Type (2020-2025) & ($ million)
Table 9. Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global Neurodegenerative Drugs Sale Price by Type (2020-2025) & (US$/MT)
Table 11. Global Neurodegenerative Drugs Sale by Application (2020-2025) & (MT)
Table 12. Global Neurodegenerative Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Neurodegenerative Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Neurodegenerative Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Neurodegenerative Drugs Sale Price by Application (2020-2025) & (US$/MT)
Table 16. Global Neurodegenerative Drugs Sales by Company (2020-2025) & (MT)
Table 17. Global Neurodegenerative Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Neurodegenerative Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Neurodegenerative Drugs Sale Price by Company (2020-2025) & (US$/MT)
Table 21. Key Manufacturers Neurodegenerative Drugs Producing Area Distribution and Sales Area
Table 22. Players Neurodegenerative Drugs Products Offered
Table 23. Neurodegenerative Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Neurodegenerative Drugs Sales by Geographic Region (2020-2025) & (MT)
Table 27. Global Neurodegenerative Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Neurodegenerative Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Neurodegenerative Drugs Sales by Country/Region (2020-2025) & (MT)
Table 31. Global Neurodegenerative Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Neurodegenerative Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Neurodegenerative Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)
Table 35. Americas Neurodegenerative Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Neurodegenerative Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 38. Americas Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 39. APAC Neurodegenerative Drugs Sales by Region (2020-2025) & (MT)
Table 40. APAC Neurodegenerative Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Neurodegenerative Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 43. APAC Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 44. Europe Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)
Table 45. Europe Neurodegenerative Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 47. Europe Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 48. Middle East & Africa Neurodegenerative Drugs Sales by Country (2020-2025) & (MT)
Table 49. Middle East & Africa Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Neurodegenerative Drugs Sales by Type (2020-2025) & (MT)
Table 51. Middle East & Africa Neurodegenerative Drugs Sales by Application (2020-2025) & (MT)
Table 52. Key Market Drivers & Growth Opportunities of Neurodegenerative Drugs
Table 53. Key Market Challenges & Risks of Neurodegenerative Drugs
Table 54. Key Industry Trends of Neurodegenerative Drugs
Table 55. Neurodegenerative Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Neurodegenerative Drugs Distributors List
Table 58. Neurodegenerative Drugs Customer List
Table 59. Global Neurodegenerative Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 60. Global Neurodegenerative Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 62. Americas Neurodegenerative Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Neurodegenerative Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 64. APAC Neurodegenerative Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 66. Europe Neurodegenerative Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Neurodegenerative Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 68. Middle East & Africa Neurodegenerative Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Neurodegenerative Drugs Sales Forecast by Type (2026-2031) & (MT)
Table 70. Global Neurodegenerative Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Neurodegenerative Drugs Sales Forecast by Application (2026-2031) & (MT)
Table 72. Global Neurodegenerative Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Novartis Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Novartis Neurodegenerative Drugs Product Portfolios and Specifications
Table 75. Novartis Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 76. Novartis Main Business
Table 77. Novartis Latest Developments
Table 78. Pfizer Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Neurodegenerative Drugs Product Portfolios and Specifications
Table 80. Pfizer Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Merck Serono Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Merck Serono Neurodegenerative Drugs Product Portfolios and Specifications
Table 85. Merck Serono Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 86. Merck Serono Main Business
Table 87. Merck Serono Latest Developments
Table 88. Biogen Idec Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Biogen Idec Neurodegenerative Drugs Product Portfolios and Specifications
Table 90. Biogen Idec Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 91. Biogen Idec Main Business
Table 92. Biogen Idec Latest Developments
Table 93. TEVA Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. TEVA Neurodegenerative Drugs Product Portfolios and Specifications
Table 95. TEVA Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 96. TEVA Main Business
Table 97. TEVA Latest Developments
Table 98. UCB Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. UCB Neurodegenerative Drugs Product Portfolios and Specifications
Table 100. UCB Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 101. UCB Main Business
Table 102. UCB Latest Developments
Table 103. Boehringer Ingelheim Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolios and Specifications
Table 105. Boehringer Ingelheim Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 106. Boehringer Ingelheim Main Business
Table 107. Boehringer Ingelheim Latest Developments
Table 108. Sanofi Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Sanofi Neurodegenerative Drugs Product Portfolios and Specifications
Table 110. Sanofi Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 111. Sanofi Main Business
Table 112. Sanofi Latest Developments
Table 113. GlaxoSmithKline Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. GlaxoSmithKline Neurodegenerative Drugs Product Portfolios and Specifications
Table 115. GlaxoSmithKline Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 116. GlaxoSmithKline Main Business
Table 117. GlaxoSmithKline Latest Developments
Table 118. Livzon Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 120. Livzon Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 121. Livzon Pharmaceutical Main Business
Table 122. Livzon Pharmaceutical Latest Developments
Table 123. Haisco Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 125. Haisco Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 126. Haisco Pharmaceutical Main Business
Table 127. Haisco Pharmaceutical Latest Developments
Table 128. Jingxin Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 130. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 131. Jingxin Pharmaceutical Main Business
Table 132. Jingxin Pharmaceutical Latest Developments
Table 133. Dongcheng Biochemicals Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolios and Specifications
Table 135. Dongcheng Biochemicals Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 136. Dongcheng Biochemicals Main Business
Table 137. Dongcheng Biochemicals Latest Developments
Table 138. Hisun Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 140. Hisun Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 141. Hisun Pharmaceutical Main Business
Table 142. Hisun Pharmaceutical Latest Developments
Table 143. Luye Pharma Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Luye Pharma Neurodegenerative Drugs Product Portfolios and Specifications
Table 145. Luye Pharma Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 146. Luye Pharma Main Business
Table 147. Luye Pharma Latest Developments
Table 148. Ark Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 150. Ark Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 151. Ark Pharmaceutical Main Business
Table 152. Ark Pharmaceutical Latest Developments
Table 153. Kanghong Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 155. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 156. Kanghong Pharmaceutical Main Business
Table 157. Kanghong Pharmaceutical Latest Developments
Table 158. Huahai Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolios and Specifications
Table 160. Huahai Pharmaceutical Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 161. Huahai Pharmaceutical Main Business
Table 162. Huahai Pharmaceutical Latest Developments
Table 163. BORA PHARMACEUTICALS Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolios and Specifications
Table 165. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (MT), Revenue ($ Million), Price (US$/MT) and Gross Margin (2020-2025)
Table 166. BORA PHARMACEUTICALS Main Business
Table 167. BORA PHARMACEUTICALS Latest Developments
LIST OF FIGURES
Figure 1. Picture of Neurodegenerative Drugs
Figure 2. Neurodegenerative Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neurodegenerative Drugs Sales Growth Rate 2020-2031 (MT)
Figure 7. Global Neurodegenerative Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Neurodegenerative Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Neurodegenerative Drugs Sales Market Share by Country/Region (2024)
Figure 10. Neurodegenerative Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of NMDA
Figure 12. Product Picture of SSRIs
Figure 13. Product Picture of Dopamine Inhibitors
Figure 14. Global Neurodegenerative Drugs Sales Market Share by Type in 2025
Figure 15. Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2025)
Figure 16. Neurodegenerative Drugs Consumed in Parkinson?s Disease
Figure 17. Global Neurodegenerative Drugs Market: Parkinson?s Disease (2020-2025) & (MT)
Figure 18. Neurodegenerative Drugs Consumed in Huntington Disease
Figure 19. Global Neurodegenerative Drugs Market: Huntington Disease (2020-2025) & (MT)
Figure 20. Neurodegenerative Drugs Consumed in Amyotrophic Lateral Sclerosis
Figure 21. Global Neurodegenerative Drugs Market: Amyotrophic Lateral Sclerosis (2020-2025) & (MT)
Figure 22. Neurodegenerative Drugs Consumed in Alzheimer?s Disease
Figure 23. Global Neurodegenerative Drugs Market: Alzheimer?s Disease (2020-2025) & (MT)
Figure 24. Global Neurodegenerative Drugs Sale Market Share by Application (2024)
Figure 25. Global Neurodegenerative Drugs Revenue Market Share by Application in 2025
Figure 26. Neurodegenerative Drugs Sales by Company in 2025 (MT)
Figure 27. Global Neurodegenerative Drugs Sales Market Share by Company in 2025
Figure 28. Neurodegenerative Drugs Revenue by Company in 2025 ($ millions)
Figure 29. Global Neurodegenerative Drugs Revenue Market Share by Company in 2025
Figure 30. Global Neurodegenerative Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 33. Americas Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 34. APAC Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 35. APAC Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 36. Europe Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 37. Europe Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 39. Middle East & Africa Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 40. Americas Neurodegenerative Drugs Sales Market Share by Country in 2025
Figure 41. Americas Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)
Figure 42. Americas Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 43. Americas Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 44. United States Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Neurodegenerative Drugs Sales Market Share by Region in 2025
Figure 49. APAC Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)
Figure 50. APAC Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 51. APAC Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 52. China Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. India Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Neurodegenerative Drugs Sales Market Share by Country in 2025
Figure 60. Europe Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)
Figure 61. Europe Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 62. Europe Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 63. Germany Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. France Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 71. Egypt Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2025
Figure 77. Manufacturing Process Analysis of Neurodegenerative Drugs
Figure 78. Industry Chain Structure of Neurodegenerative Drugs
Figure 79. Channels of Distribution
Figure 80. Global Neurodegenerative Drugs Sales Market Forecast by Region (2026-2031)
Figure 81. Global Neurodegenerative Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Neurodegenerative Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Neurodegenerative Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Neurodegenerative Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Neurodegenerative Drugs Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Neurodegenerative Drugs
Figure 2. Neurodegenerative Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neurodegenerative Drugs Sales Growth Rate 2020-2031 (MT)
Figure 7. Global Neurodegenerative Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Neurodegenerative Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Neurodegenerative Drugs Sales Market Share by Country/Region (2024)
Figure 10. Neurodegenerative Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of NMDA
Figure 12. Product Picture of SSRIs
Figure 13. Product Picture of Dopamine Inhibitors
Figure 14. Global Neurodegenerative Drugs Sales Market Share by Type in 2025
Figure 15. Global Neurodegenerative Drugs Revenue Market Share by Type (2020-2025)
Figure 16. Neurodegenerative Drugs Consumed in Parkinson?s Disease
Figure 17. Global Neurodegenerative Drugs Market: Parkinson?s Disease (2020-2025) & (MT)
Figure 18. Neurodegenerative Drugs Consumed in Huntington Disease
Figure 19. Global Neurodegenerative Drugs Market: Huntington Disease (2020-2025) & (MT)
Figure 20. Neurodegenerative Drugs Consumed in Amyotrophic Lateral Sclerosis
Figure 21. Global Neurodegenerative Drugs Market: Amyotrophic Lateral Sclerosis (2020-2025) & (MT)
Figure 22. Neurodegenerative Drugs Consumed in Alzheimer?s Disease
Figure 23. Global Neurodegenerative Drugs Market: Alzheimer?s Disease (2020-2025) & (MT)
Figure 24. Global Neurodegenerative Drugs Sale Market Share by Application (2024)
Figure 25. Global Neurodegenerative Drugs Revenue Market Share by Application in 2025
Figure 26. Neurodegenerative Drugs Sales by Company in 2025 (MT)
Figure 27. Global Neurodegenerative Drugs Sales Market Share by Company in 2025
Figure 28. Neurodegenerative Drugs Revenue by Company in 2025 ($ millions)
Figure 29. Global Neurodegenerative Drugs Revenue Market Share by Company in 2025
Figure 30. Global Neurodegenerative Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 33. Americas Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 34. APAC Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 35. APAC Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 36. Europe Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 37. Europe Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Neurodegenerative Drugs Sales 2020-2025 (MT)
Figure 39. Middle East & Africa Neurodegenerative Drugs Revenue 2020-2025 ($ millions)
Figure 40. Americas Neurodegenerative Drugs Sales Market Share by Country in 2025
Figure 41. Americas Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)
Figure 42. Americas Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 43. Americas Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 44. United States Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Neurodegenerative Drugs Sales Market Share by Region in 2025
Figure 49. APAC Neurodegenerative Drugs Revenue Market Share by Region (2020-2025)
Figure 50. APAC Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 51. APAC Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 52. China Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. India Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Neurodegenerative Drugs Sales Market Share by Country in 2025
Figure 60. Europe Neurodegenerative Drugs Revenue Market Share by Country (2020-2025)
Figure 61. Europe Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 62. Europe Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 63. Germany Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. France Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Application (2020-2025)
Figure 71. Egypt Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Neurodegenerative Drugs Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2025
Figure 77. Manufacturing Process Analysis of Neurodegenerative Drugs
Figure 78. Industry Chain Structure of Neurodegenerative Drugs
Figure 79. Channels of Distribution
Figure 80. Global Neurodegenerative Drugs Sales Market Forecast by Region (2026-2031)
Figure 81. Global Neurodegenerative Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Neurodegenerative Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Neurodegenerative Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Neurodegenerative Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Neurodegenerative Drugs Revenue Market Share Forecast by Application (2026-2031)
More Publications
Global Oxytocic Pharmaceuticals Market Growth 2025-2031
US$ 3,660.00
October 2025
90 pages
Global Genotyping Market Growth 2024-2030
US$ 3,660.00
September 2024
109 pages
Global Breathing System Filters Market Growth 2024-2030
US$ 3,660.00
December 2024
128 pages
Global Channel Infusion Pumps Market Growth 2026-2032
US$ 3,660.00
January 2025
141 pages
Global Gene Amplification Technologies Market Growth (Status and Outlook) 2024-2030
US$ 3,660.00
March 2024
130 pages
